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Healthcare workers (n = 803) with mild symptoms were 
tested for severe acute respiratory syndrome corona-
virus 2 (SARS-CoV-2) (n = 90 positive) and asked to 
complete a symptom questionnaire. Anosmia, muscle 
ache, ocular pain, general malaise, headache, extreme 
tiredness and fever were associated with positivity. A 
predictive model based on these symptoms showed 
moderate discriminative value (sensitivity: 91.2%; 
specificity: 55.6%). While our models would not justify 
presumptive SARS-CoV-2 diagnosis without molecular 
confirmation, it can contribute to targeted screening 
strategies.
Following the emergence of severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2) in China 
in December 2019, countries worldwide strive to con-
tain or slow down virus transmission to allow health 
facilities to cope with the rapid rise of patients with 
coronavirus disease (COVID-19) [1,2]. In February 2020, 
the first patient with COVID-19 was reported in the 
Netherlands. Cases initially clustered in the province of 
Noord Brabant, followed by dissemination across the 
country [3].
Healthcare workers (HCW) are disproportionally at risk 
of contracting SARS-CoV-2 [4]. To protect HCW and 
prevent nosocomial transmission, it is recommended 
that healthcare facilities have a strategy for testing, 
management and follow-up of HCW with respiratory 
symptoms [2,4]. Test results also guide when an HCW 
can return to work with mild symptoms. Unfortunately, 
national and institutional strategies are in part depend-
ent on the operational feasibility.
Here, we present our findings from a large cohort of 
symptomatic HCW who were tested for SARS-CoV-2 
infection as part of our hospital programme. We aimed 
to identify symptoms associated with test positivity 
and develop a diagnostic model to predict SARS-CoV-2 
infection based on early symptoms. In a context of lim-
ited availability of testing supplies, prediction models 
may support targeted testing strategies and guidelines 
to refrain from or resume clinical duties.
Screening of healthcare workers
Since early March 2020, HCW in our hospital have been 
tested for SARS-CoV-2 when they have symptoms sug-
gestive of COVID-19 according to institutional policy 
based on the latest evidence. All 1,247 HCW tested 
between 10 and 29 March 2020 received an email 
with a link to an online anonymous questionnaire on 
the symptoms they experienced before their test. We 
received 803 completed questionnaires, an overall 
response rate of 64%. By 29 March, there had been 112 
HCW with a positive test, of whom 90 responded to the 
questionnaire, which suggests a slight overrepresenta-
tion of test-positives among the respondents (response 
rate 80%).
Initially, the questionnaire covered respiratory and 
general non-respiratory symptoms and was completed 
by 627 HCW (56 SARS-CoV-2-positive) between 10 and 
23 March 2020. After reports on anosmia and gastro-
intestinal illness in the initial COVID-19 patients, the 
questionnaire was adapted on 24 March to also include 
anosmia, diarrhoea, nausea and extreme tiredness. 
This updated questionnaire was completed by 176 HCW 
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(34 positives) between 24 and 30 March 2020. Most 
respondents were female (82.9%) and between 21 and 
40 years-old (55.7%) (Table 1).
To allow a diagnostic model to be created based on 
the initial cohort (627 HCW) and tested in the second 
cohort (176 HCW), all HCW who were tested positive 
before 24 March (n = 77) and a random selection (n = 
99) of the HCW who tested negative before 24 March 
received an additional questionnaire asking about 
these four additional symptoms separately. This addi-
tional questionnaire was completed by 45 SARS-CoV-2-
positive and 48 negative HCW.
Symptoms associated with SARS-CoV-2-
positive test results
The most frequently reported symptoms among test-
negative HCW were cough (60%), sore throat (56%) 
and common cold (51%). Test-positive HCW most fre-
quently reported headache (71%), general malaise 
(63%) and muscle ache (63%) (Table 2). Among 176 
HCW who responded to the second questionnaire after 
24 March, HCW who tested positive for SARS-CoV-2 
had a median of four symptoms (interquartile range 
(IQR): 2–6) compared with three symptoms (IQR: 2–5) 
for HCW who tested negative (p = 0.004).
Univariate associations were assessed by calculating 
odds ratios. General non-respiratory symptoms (mus-
cle ache, ocular pain, general malaise, headache and 
extreme tiredness) were associated with test positiv-
ity. Anosmia was reported by 47% of test-positives 
and was strongly associated with SARS-CoV-2 positiv-
ity (OR = 23.0; 95% confidence interval (CI): 8.2–64.8). 
Among the 14 people with anosmia in whom other 
symptoms were also recorded, 10 reported a runny 
nose and/or sneezing, while four did not report any 
symptoms that can cause nasal congestion. Among 10 
individuals with both anosmia and muscle ache, nine 
were SARS-CoV-2-positive. None of the respiratory 
symptoms were associated with SARS-CoV-2 positivity, 
sore throat being less common among test positives 
(40.0% vs 56.1%; p = 0.004). Symptoms reported by 
test-positive HCW are presented in a heat map indicat-
ing which symptoms were reported together (Figure 1).
Data from the initial cohort (627 HCW) were used 
to predict the SARS-CoV-2 test result in the second 
cohort (176 HCW). A prediction model was fit on all 
Table 1
Description of the study population of healthcare workers tested for SARS-CoV-2, by PCR result, the Netherlands, March 
2020 (n = 803)
Total 
 
n = 803
SARS-CoV-2-positive 
 
n = 90
SARS-CoV-2-negative 
 
n = 713
n % n % n %
Sexa
Male 141 17.6 19 21.1 122 17.1
Female 661 82.4 71 78.9 590 82.9
Age group (years)
< 20 10 1.2 0 0.0 10 1.4
21–30 216 26.9 24 26.7 192 26.9
31–40 231 28.8 22 24.4 209 29.3
41–50 173 21.5 25 27.8 148 20.8
51–60 133 16.6 16 17.8 117 16.4
> 60 40 5.0 3 3.3 37 5.2
Comorbidities (one or more)
Chronic lung disease 61 7.6 4 4.4 57 8.0
Disease of immune system 29 3.6 0 0.0 29 4.1
Allergy 137 17.1 8 8.9 129 18.1
Medical profession
Medical doctor 144 17.9 21 23.3 123 17.3
Nurse 266 33.1 31 34.4 235 33.0
Other healthcare worker 393 48.9 38 42.2 355 49.8
Questionnaire
Initial questionnaire (for development of model) 627 78.1 56 62.2 571 80.1
Extended questionnaire (for validation of the model) 176 21.9 34 37.8 142 19.9
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
a For one person information on sex was missing.
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symptoms using Lasso regression (STATA version 16.0; 
Statacorp, Texas, United States) [5]. This is a tech-
nique that attempts to reduce overfitting by shrink-
ing coefficients. Some coefficients are shrunk to zero 
and hence effectively removed from the model. The 
model retained all variables except fever and cough. 
This model achieved an area under the ROC (receiver 
operating characteristic) curve of 0.754 (95% CI: 
0.662–0.846) (Figure 2A) and achieved a sensitivity of 
82.4% and specificity of 59.2%. A simple model which 
included all the symptoms with a significant positive 
association, weighted based on the results in  Table 
2 (weight of 3 for anosmia, 2 for muscle ache and 1 each 
for extreme tiredness, headache, ocular pain fever, and 
general malaise) achieved an area under the ROC curve 
of 0.783 (95% CI: 0.696–0.870) (Figure 2B). Using a 
cut-off of ≥ 3 symptoms gave a sensitivity of 91.2% and 
a specificity of 55.6% for SARS-CoV-2 test positivity.
Discussion
This study provides valuable insights in the early symp-
toms of COVID-19 in a large cohort of HCW. General 
non-respiratory symptoms (muscle ache, ocular pain, 
general malaise, headache, extreme tiredness and 
fever) were most frequently reported by test-positive 
HCW and these symptoms were strongly associated 
with SARS-CoV-2 test positivity, unlike respiratory 
symptoms such as cough and sneezing. Anosmia was 
particularly strongly associated with test positivity. 
Fever and cough have been reported as early symp-
toms in mild COVID-19 cases [6], and fever occurs in 
the majority of individuals hospitalised for COVID-19 
[7]. However, in our study fever was not the strongest 
predictor of test positivity among HCW, which is in line 
with findings from a similar study from the Netherlands 
[8].
Recent work from the Netherlands showed that 63% 
of HCW had worked despite mild symptoms [8]. Clear 
guidance on the use of personal protective equipment 
(PPE) and clear protocols for work abstinence dur-
ing symptoms are vital to protect HCW and patients. 
Models of triage and diagnosis may help physicians 
and public health authorities to estimate infection 
risk and support decisions about such isolation and 
quarantine measures [9]. Our simple prediction model 
based on the seven symptoms most strongly associ-
ated with SARS-CoV-2 positivity among HCW, giving 
extra weight to anosmia and muscle ache as strong-
est predictors, gave a high sensitivity (91.2%) and a 
moderate specificity (55.6%). Where the sensitivity 
and specificity of a diagnostic test or prediction algo-
rithm are features of the test, the positive predictive 
value (PPV) and negative predictive value (NPV) are 
related to the infection prevalence in the population. 
With increasing prevalence, the PPV increases and NPV 
decreases. With a prevalence of infection of 10%, the 
above sensitivity and specificity would result in a PPV 
Table 2
Univariate associations of early symptoms with SARS-CoV2 PCR positivity among healthcare workers, the Netherlands, 
March 2020 (n = 803)
Symptom SARS-CoV2-positive SARS-CoV2-negative OR (95% CI) p value
n/N % n/N %
General non-respiratory symptoms
Anosmiaa 37/79 46.8 7/190 3.7 23.0 (8.2–64.8) < 0.001
Muscle ache 57/90 63.3 143/713 20.1 6.9 (4.2–11.3) < 0.001
Ocular pain 31/90 34.4 75/713 10.5 4.5 (2.7–7.4) < 0.001
General malaise 57/90 63.3 208/713 29.2 4.2 (2.6–6.7) < 0.001
Headache 64/90 71.1 296/713 41.5 3.5 (2.1–5.7) < 0.001
Extreme tirednessa 45/79 57.0 61/190 32.1 2.8 (1.6–4.9) < 0.001
Fever 51/90 56.7 233/713 32.7 2.7 (1.7–4.2) < 0.001
Respiratory symptoms
Common cold 50/90 55.6 363/713 50.9 1.2 (0.8–1.9) 0.406
Sneeze 36/90 40.0 253/713 35.5 1.2 (0.8–1.9) 0.401
Cough 53/90 58.9 424/713 59.5 1.0 (0.6–1.5) 0.916
Shortness of breath 20/90 22.2 157/713 22.0 1.0 (0.6–1.7) 0.965
Runny nose 24/90 26.7 231/713 32.4 0.8 (0.5–1.2) 0.271
Sore throat 36/90 40.0 400/713 56.1 0.5 (0.3–0.8) 0.004
Gastrointestinal symptoms
Nauseaa 13/79 16.5 17/190 8.9 2.0 (0.9–4.4) 0.075
Diarrhoeaa 14/79 17.7 20/190 10.5 1.8 (0.9–3.9) 0.106
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
a The total here includes only those respondents of the second response cohort (34 cases and 142 non-cases) and those from the first cohort 
who responded to the additional questions (45 cases and 48 non-cases).
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of 16.9% and NPV of 98.5%. This is very informative, 
as with only 1.5% chance of having SARS-CoV-2 upon 
a negative ‘prediction’, hospitals could consider letting 
those HCW work (with PPE), depending on the shortage 
of staff. Because of the low specificity, about half of 
HCW would be predicted as ‘positive’. However, test-
ing only this subgroup of ‘predicted positives’ would 
reduce the necessary testing materials by 50%.
A unique aspect of our study is that we assessed early 
symptoms of COVID-19 in an otherwise healthy popula-
tion. The HCW received the invitation to the question-
naire the day after receiving their test result, which 
was usually within 24 h after the sample was taken, 
thus minimising recall bias. The response rate was 
64%, and selection bias could have occurred as peo-
ple with atypical (i.e. non-respiratory symptoms) could 
have been more likely to respond to the questionnaire, 
leading to an overrepresentation of people with these 
symptoms. However, as the percentage of respiratory 
symptoms among test-positive and test-negative HCW 
was comparable, we do not expect that this could have 
explained the strong associations observed in this 
study. Our anonymous data collection did not allow 
us to examine initial symptoms in relation to disease 
progression. The study design would have allowed for 
the calculation of relative risks (RR), were it not that we 
had asked for four symptoms in a case–control manner. 
Even though RR are easier to interpret than OR, and OR 
may slightly overestimate the risk estimate, presenting 
a mix of RR and OR would have been confusing. In addi-
tion, presenting the OR with column percentages gives 
the useful insight of the percentage of cases (and non-
cases) that reported a certain symptoms.
Conclusion
Our findings may be used to refine national public 
health guidelines on self-isolating individuals whose 
symptoms are suggestive of COVID-19. The current pol-
icy in the Netherlands is that people with mild respira-
tory symptoms self-isolate and household members 
of people with fever are requested to self-quarantine. 
Based on our findings, this could be expanded with 
general non-respiratory symptoms or anosmia. Our 
detailed report of early symptoms among HCW tested 
for SARS-CoV-2 identified that general non-respiratory 
symptoms and anosmia were strongly associated with 
test positivity. While our prediction models would not 
justify presumptive SARS-CoV-2 diagnosis without 
molecular confirmation, findings may contribute to a 
targeted screening strategy which may be of value in 
settings with limited availability of testing materials.
Figure 1
Heatmap of early symptoms reported by healthcare 
workers positive for SARS-CoV-2, the Netherlands, March 
2020 (n = 90)
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General symptomsRespiratory symptoms GI
GI: gastrointestinal; SARS-CoV-2: severe acute respiratory 
syndrome coronavirus 2.
Symptoms were grouped as respiratory, general and 
gastrointestinal symptoms. Green: symptom is present; grey: 
symptom is absent; blank: not recorded.
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